MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30.

Income Overview

Net Income
-$57,457K
EPS
-$0.65
Unit: Thousand (K) dollars

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-09-30
Collaboration revenue
0 4,015 2,926 2,910
In-process research and development
0 0 -6,706
Research and development
49,193 40,451 36,872 37,200
General and administrative
10,945 10,042 10,690 9,526
Total operating expenses
60,138 50,493 47,562 53,432
Loss from operations
-60,138 -46,478 -44,636 -50,522
Interest income
2,681 3,081 2,996 3,422
Net loss
-57,457 -43,397 -41,640 -47,100
Earnings per share, basic
-0.65 -0.5 -0.52 -0.78
Earnings per share, diluted
-0.65 -0.5 -0.52 -0.78
Weighted average number of shares outstanding, basic
87,957,868 87,010,742 79,410,354 60,205,327
Weighted average number of shares outstanding, diluted
87,957,868 87,010,742 79,410,354 60,205,327
Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss-$57,457K Interest income$2,681K Loss from operations-$60,138K Total operatingexpenses$60,138K General andadministrative$10,945K Research and development$49,193K

Immunome Inc. (IMNM)

Immunome Inc. (IMNM)